Shots:

• In the P-I SPICE study- the companies will evaluate the clinical combination of BMS’ Opdivo with PsiOxus’ NG-641 and optimize the combination IV dosing regimen in late-stage cancer patients to treat a range of tumor types
• PsiOxus will be responsible to conduct P-I study with patient recruitment expected to initiate in Q3’21
• NG-641 is a tumor re-engineering product using PsiOxus’ T-SIGn platform based upon the enadenotucirev vector while Opdivo is a PD-1 immune checkpoint inhibitor- designed to harness the body’s own immune system to help restore anti-tumor immune response

  Ref: Businesswire | Image: BMS